Update from ESGO 2026 – PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort

Prof. Domenica "Ketta" Lorusso obtained her degree in Medicine and Surgery in 1995, her residency in Obstetrics and Gynecology in 1999 and her PhD in Obstetrics and Gynecology in 2003. She is currently Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and responsible for clinical research at Fondazione Policlinico Gemelli IRCCS.

She is an active member of the European Network of Gynaecological Oncological Trial groups (ENGOT), where she leads the Gynecological Cancer Academy (since 2020). Dr Lorusso is a member of the Board of Directors of the Gynecologic Cancer InterGroup (GCIG), where she is the past chair of the Endometrial Cancer Committee and the Nomination and Meeting Committee. Currently, she is a member of the ESGO Council and scientific coordinator of the ESMO Gynaecological Cancers Congress. She is involved in preclinical and clinical research in gynaecological cancer, and she is the author of more than 250 papers on gynaecological cancers. Her work has hugely contributed to improving the quality of care and clinical outcome and to reducing the toxicity of treatments in women with advanced gynaecological malignancies.

Medical oncologist at the Institut de Cancérologie de l’Ouest and a researcher in Team 7 of CRCI2NA. He is also affiliated with the PISTER programme of SIRIC ILIAD, dedicated to cellular oncology.

His research focuses on two main areas: circulating cancer biomarkers for the detection and characterisation of solid tumours through blood-based approaches, and epigenetics, specifically the mechanisms acquired by cancer cells over time and under treatment pressure.

His work aims to better understand treatment resistance and to develop epigenetic strategies to prevent or overcome it, with current research spanning brain tumours, gynecological cancers, and breast cancer.